Last reviewed · How we verify
Prosicca sine
Prosicca sine is a mucin-based bioadhesive formulation designed to provide sustained lubrication and protection to the ocular surface in dry eye disease.
Prosicca sine is a mucin-based bioadhesive formulation designed to provide sustained lubrication and protection to the ocular surface in dry eye disease. Used for Severe dry eye syndrome / keratoconjunctivitis sicca.
At a glance
| Generic name | Prosicca sine |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | Artificial tear / ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The drug consists of a mucin-containing polymer that adheres to the corneal and conjunctival epithelium, forming a protective layer that reduces friction, maintains moisture, and protects against further epithelial damage. By mimicking natural tear film components, it provides symptomatic relief and supports ocular surface healing in patients with severe dry eye syndrome.
Approved indications
- Severe dry eye syndrome / keratoconjunctivitis sicca
Common side effects
- Transient blurred vision
- Eye irritation
- Foreign body sensation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prosicca sine CI brief — competitive landscape report
- Prosicca sine updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI